Verdenafil improves patient satisfaction with erection hardness, orgasmic function and overall sexual experience, while improving quality of life in men with erectile dysfunction

Journal of Sexual Medicine

Volumn 1, Issue 2, 2004, Pages 185-192

  Donatucci, Craig ^a   Taylor, Terry ^b   Thibonnier, Marc ^b   Bangerter, Keith ^b   Gittelman, Marc ^c   Casey, Richard ^d   Abele, Randall P ^e   Andriole, Gerald L ^f   Auerbach, Stephen M ^g   Barkin, Jack ^h   Barzell, Winston ⁱ   Bergner, Donald ^j   Childs, Stacy ^k   Cohen, Selwyn ^l   Cook, David O ^m   Deeths, Jeoffrey ⁿ   Elhilali, Mostafa M ^o   Ellsworth, Pamela I ^p   Epstein, Howard B ^q   Feldman, Robert A ^r   Fields, Louis ^h   Fincher, Roger ^h   Fitch III, William ^s   Foote, Jenelle E ^h   Frankel, Jeffrey ^h   Fuselier, Harold A ^t   Gilderman, Larry I ^u   Goldfischer, Evan ^v   Gottesman, James E ^w   Govier, Fred ^x   Greenspan, Michael ^y   Hellstrom, Wayne J ^z   Herring, Charles B ^aa   Karlin, Gary S ^ab   Kaufman, Joel M ^ac   Krane, Robert J ^ad   Krieger, John N ^ae   Lau, Allan ^af   Leitner, William A ^ag   Lilly, Joel ^v   Lubensky, Jack ^ah   Maruf, Nizamuddin ^ai   Matthews, Keith ^h   McCullough, Andrew ^aj   McVary, Kevin T ^ak   Melman, Arnold ^al   Monnig, William B ^am   Neiderberger, Craig ^af   Padma Nathan, Harin ^an   Patrick, Allan B ^h   Peterson, Jon Lee ^h   Pommerville, Peter J ^h   Price, Gary V ^ao   Raad, George ^ap   Sieber, Paul R ^aq   Skolnick, Alan W ^h   Steidle, Christopher P ^ar   Storrie, Cecile ^as   Talley, David ^at   Tepas, Joseph J ^q   Truitt, Timothy S ^au   Valiquette, Luc ^av   Vukasin, Alexander ^aw   Wiatrak, Mitchell ^ax   Williams, John ^q   Wurzel, Rafael ^ay   Zadra, Joseph ^h   more..

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b BAYER CORPORATION   (United States)

^c South Florida Medical Research   (United States)

^d The Male Health Centers   (Canada)

^e Edmonton Prostate Centre   (Canada)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g California Professional Research   (United States)

^h Urology Treatment Center ^*

ⁱ Urology Treatment Center   (United States)

^j Tampa Bay Medical Research   (United States)

^k Wyoming Research Foundation   (United States)

^l Clinical Research Consultants Inc   (United States)

^m Piedmont Medical Research Associates   (United States)

ⁿ Nebraska Clinical Research Center   (United States)

^o ROYAL VICTORIA HOSPITAL   (Canada)

^p DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^q UNIVERSITY OF FLORIDA HEALTH SCIENCE CENTER   (United States)

^r CT Clinical Research Center   (United States)

^s Urology Consultants   (United States)

^t OCHSNER MEDICAL CENTER   (United States)

^u Univ Clinical Research Assoc Inc   (United States)

^v Hudson Valley Urology   (United States)

^w Seattle Urological Associates   (United States)

^x VIRGINIA MASON MEDICAL CENTER   (United States)

^y Hamilton/Dist Urol Assoc   (United States)

^z TULANE UNIVERSITY MEDICAL CENTER   (United States)

^aa New Hanover Med Res Assocs   (United States)

^ab Lawrenceville Urology   (United States)

^ac Urology Research Options   (United States)

^ad MASSACHUSETTS GENERAL HOSPITAL   (United States)

^ae Puget Sound Health Care System   (United States)

^af UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^ag Urology Centers of Alabama   (United States)

^ah RADIANT RESEARCH   (United States)

^ai MidAtlantic Clinical Research Center   (United States)

^aj NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^ak Northwestern Center for Clinical Research   (United States)

^al MONTEFIORE MEDICAL CENTER   (United States)

^am Urology Group   (United States)

^an The Male Clinic   (United States)

^ao Medical Clinic of North Texas   (United States)

^ap Metrolina Nephrology Associates   (United States)

^aq Urological Associates of Lancaster   (United States)

^ar Northeast Indiana Urology   (United States)

^as MDS Inc   (Canada)

^at Urology San Antonio Research   (United States)

^au Health Advance Institute   (United States)

^av UNIVERSITY OF MONTREAL   (Canada)

^aw Princeton Eye Group   (United States)

^ax Midwest Research Specialists   (United States)

^ay Grove Hill Medical Center   (United States)

more..

Author keywords

Erectile dysfunction; IIEF domain scores; PDE5 inhibitor; Secondary efficacy Variables; Vardenafil

Indexed keywords

PLACEBO; VARDENAFIL; IMIDAZOLE DERIVATIVE; PHOSPHODIESTERASE INHIBITOR; PIPERAZINE DERIVATIVE; SULFONE; TRIAZINE DERIVATIVE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSPEPSIA; ERECTILE DYSFUNCTION; FLUSHING; HEADACHE; HETEROSEXUALITY; HUMAN; MALE; MULTICENTER STUDY; ORGASM; PATIENT SATISFACTION; PENIS ERECTION; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SELF REPORT; SEXUAL AROUSAL; SEXUAL BEHAVIOR; SEXUAL INTERCOURSE; SIDE EFFECT; STATISTICAL SIGNIFICANCE; ADULT; CANADA; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; IMPOTENCE; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; PSYCHOLOGICAL ASPECT; TIME; TREATMENT OUTCOME; UNITED STATES;

ADULT; CANADA; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FLUSHING; HEADACHE; HUMANS; IMIDAZOLES; IMPOTENCE; MALE; PATIENT SATISFACTION; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PLACEBOS; QUALITY OF LIFE; QUESTIONNAIRES; SEXUAL BEHAVIOR; SULFONES; TIME FACTORS; TREATMENT OUTCOME; TRIAZINES; UNITED STATES;

EID: 20144369749     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2004.04027.x     Document Type: Article

References (22)

1. NIH Consensus Conference. Impotence. NIH consensus development panel on impotence. JAMA 1993;270:83-90.
2. Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999;84:50-6.
3. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: Prevalence and predictors. JAMA 1999;281:537-44.
4. Levine LA. Diagnosis and treatment of erectile dysfunction. Am J Med 2000;109(9A Suppl):3S-12S; Discussion 29S-30S.
5. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: Results of the Massachusetts male aging study. J Urol 1994;151:54-61.
6. Chew KK, Earle CM, Stuckey BG, Jamrozik K, Keogh EJ. Erectile dysfunction in general medicine practice: Prevalence and clinical correlates. Int J Impot Res 2000;12:41-5.
7. Seidman SN. Exploring the relationship between depression and erectile dysfunction in aging men. J Clin Psychiatry 2002;63(5 Suppl):5-12; Discussion 23-15.
8. Shabsigh R, Zakaria L, Anastasiadis AG, Seidman AS. Sexual dysfunction and depression: Etiology, prevalence, and treatment. Curr Urol Rep 2001;2:463-7.
9. Fujisawa M, Sawada K, Okada H, Arakawa S, Saito S, Kamidono S. Evaluation of health-related quality of life in patients treated for erectile dysfunction with Viagra (sildenafil citrate) using SF-36 score. Arch Androl 2002;48:15-21.
10. Giuliano F, Hultling C, El Masry WS, Smith MD, Osterloh IH, Orr M, Maytom M. Randomized trial of sildenafil for the treatment of erectile dysfunction in spinal cord injury. Sildenafil Study Group. Ann Neurol 1999;46:15-21.
11. Langtry HD, Markham A. Sildenafil: A review of its use in erectile dysfunction. Drugs 1999;57:967-89.
12. Palmer JS, Kaplan WE, Firlit CF. Erectile dysfunction in patients with spina bifida is a treatable condition. J Urol 2000;164:958-61.
13. Tsujimura A, Yamanaka M, Takahashi T, Miura H, Nishimura K, Koga M, Iwasa A, Takeyama M, Matsumiya K, Takahara S, Okuyama A. The clinical studies of sildenafil for the ageing male. Int J Androl 2002;25:28-33.
14. Wagner G, Montorsi F, Auerbach S, Collins M. Sildenafil citrate (VIAGRA) improves erectile function in elderly patients with erectile dysfunction: A subgroup analysis. J Gerontol a Biol Sci Med Sci 2001;56:M113-19.
15. Eardley I, Carledge J. Tadalafil (cialis (trademark)) for men with erectile dysfunction. Int J Clin Pract 2002;56:300-4.
16. Porst H, Rosen R, Padma-Nathan H, Goldstein I, Giuliano F, Ulbrich E, Bandel T. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: The first at-home clinical trial. Int J Impot Res 2001;13:192-9.
17. Mirone V, Donatucci C, Eardley I, McVary K, Thibonnier M. Vardenafil improves erectile dysfunction in men with erectile dysfunction regardless of etiology or baseline severity. European Society of Andrological Urology (ESAU), Capri, Italy, October 23-24, 2003.
18. Porst H, Young JM, Schmidt AC, Buvat J. Efficacy and tolerability of vardenafil for treatment of erectile dysfunction in patient subgroups. Urology 2003;62:519-23; Discussion 523-14.
19. Hellstrom WJ, Gittelman M, Karlin G, Segerson T, Thibonnier M, Taylor T, Padma-Nathan H. Vardenafil for treatment of men with erectile dysfunction: Efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 2002;23:763-71.
20. Hellstrom WJ, Gittelman M, Karlin G, Segerson T, Thibonnier M, Taylor T, Padma-Nathan H. Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: Results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology 2003;61:8-14.
21. Paige NM, Hays RD, Litwin MS, Rajfer J, Shapiro MF. Improvement in emotional well-being and relationships of users of sildenafil. J Urol 2001;166:1774-8.
22. Muller MJ, Ruof J, Graf-Morgenstern M, Porst H, Benkert O. Quality of partnership in patients with erectile dysfunction after sildenafil treatment. Pharmacopsychiatry 2001;34:91-5.